Age-Related Macular Degeneration (AMD) and Diabetic Retinopathy are leading causes of sight loss.

The incidence of Age-related Macular Degeneration and Diabetic Retinopathy, both inflammatory diseases of the eye, is rising as a result of obesity and an ageing population. Age-Related Macular Degeneration (AMD) is the leading cause of vision loss in the UK - affecting more than 600,000 people. Diabetic Retinopathy is the leading cause of visual impairment and blindness in working-age people.  There are currently no cures for either condition, and treatments are often invasive and distressing.

Dr Mark Young of Cardiff University

The research will be directed by Dr Mark Young (pictured above), who will supervise a PhD Studentship. It will build on results from a recent paper in the journal Science demonstrating that blocking P2X7 function blocks disease progression in mouse models, and a Welsh government-funded PhD project (also led by Dr Mark Young) which discovered a novel function for a drug-like compound (named C25) in blocking P2X7 function. The project aims to test and validate C25 to make it ready for next stage development.

This project was evaluated by our eminent Scientific Advisory Committee and was rated very highly. It has therefore been selected as the subject of the National Eye Research Centre’s 2018 fundraising appeal.  Total costs for the three-year project are £89,000. £18,935 has already been pledged by Cardiff University School of Biosciences towards the costs of consumables leaving approximately £70,000 to be raised through this appeal.

Please support our appeal with a donation now and help bring forward the day when we can successfully treat eye diseases like age-related macular degeneration (AMD) and diabetic retinopathy.